ATR and ovarian cancer: Chromosomal breaks in mitosis, indicative of unrepaired DSBs, are more pronounced for the PARP–ATR inhibitor combination, which is also more effective in inducing tumor regression in ovarian cancer PDX models (Kim et al. 2017).